CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present seven poster presentations at the 2016 Genitourinary Cancers Symposium taking place January 7-9, 2016 in San Francisco.
The company’s molecular information products, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient’s cancer. The data to be presented at the Genitourinary Cancer Symposium provide further supporting evidence of the clinical utility of Foundation Medicine’s assays in the care of patients with genitourinary malignancies.
